Page last updated: 2024-11-08

ahr 5333

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID173727
CHEMBL ID17436
SCHEMBL ID6440267
MeSH IDM0156349

Synonyms (18)

Synonym
ahr 5333
CHEMBL17436 ,
bdbm50017371
1-[4-(3-{4-[bis-(4-fluoro-phenyl)-hydroxy-methyl]-piperidin-1-yl}-propoxy)-3-methoxy-phenyl]-ethanone
1-[4-[3-[4-[bis(4-fluorophenyl)-hydroxymethyl]piperidin-1-yl]propoxy]-3-methoxyphenyl]ethanone
1-(4-(3-(4-(bis(4-fluorophenyl)hydroxymethyl)-1-piperidinyl)propoxy)-3-methoxyphenyl)ethanone
ethanone, 1-(4-(3-(4-(bis(4-fluorophenyl)hydroxymethyl)-1-piperidinyl)propoxy)-3-methoxyphenyl)-
60284-71-1
ahr-5333
unii-qpz94zjf1p
qpz94zjf1p ,
QFUKWQQHSSRPQM-UHFFFAOYSA-N
1-[4-[3-[4-[bis(4-fluorophenyl)hydroxymethyl]-1-piperidinyl]propoxy]-3-methoxyphenyl]ethanone
SCHEMBL6440267
DTXSID60209032
ahr-5333 b
PD160054
AKOS040745529

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" The drugs were quantitated in samples from bioavailability studies performed in dogs."( Determination of a new anti-allergenic agent, 1-[4-[3-[4-[bis-(4-fluorophenyl)hydroxymethyl]-1-piperidinyl] propoxy]-3-methoxyphenyl]ethanone, and its active acidic metabolite in plasma by high-performance liquid chromatography.
Cheng, LK; Greene, SV; Krebs, HA; Lemieux, RE, 1990
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID188953Oral antiallergy activity in the passive foot anaphylaxis (PFA) model of rat, at a dose of 10 (mg/kg); Activity greater than positive control group1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Synthesis and antiallergy activity of 4-(diarylhydroxymethyl)-1-[3-(aryloxy)propyl]piperidines and structurally related compounds.
AID188960Oral antiallergy activity in the passive foot anaphylaxis (PFA) model of rat, at a dose of 3.16 (mg/kg); Activity equal to positive control group1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Synthesis and antiallergy activity of 4-(diarylhydroxymethyl)-1-[3-(aryloxy)propyl]piperidines and structurally related compounds.
AID171866Antihypertensive activity expressed as change in mean arterial blood pressure (MABP) in spontaneously hypertensive rats (SHR), at 3-6h after 30 mg/kg oral administration1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Synthesis, calcium-channel-blocking activity, and antihypertensive activity of 4-(diarylmethyl)-1-[3-(aryloxy)propyl]piperidines and structurally related compounds.
AID171865Antihypertensive activity expressed as change in mean arterial blood pressure (MABP) in spontaneously hypertensive rats (SHR),at 0.5-2h after 30 mg/kg oral administration1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Synthesis, calcium-channel-blocking activity, and antihypertensive activity of 4-(diarylmethyl)-1-[3-(aryloxy)propyl]piperidines and structurally related compounds.
AID76319Oral antiallergy activity in the guinea pig anaphylaxis (GPA) model, at a pretreatment time of 1 h1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Synthesis and antiallergy activity of 4-(diarylhydroxymethyl)-1-[3-(aryloxy)propyl]piperidines and structurally related compounds.
AID86589Inhibitory activity against Tritiated [3H]- mepyramine binding to histamine H1 receptor in guinea pig cerebral cortex1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Synthesis and antiallergy activity of 4-(diarylhydroxymethyl)-1-[3-(aryloxy)propyl]piperidines and structurally related compounds.
AID188948Oral antiallergy activity in the passive foot anaphylaxis (PFA) model of rat, at a dose of 1.0 (mg/kg); not significantly different from negative control group1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Synthesis and antiallergy activity of 4-(diarylhydroxymethyl)-1-[3-(aryloxy)propyl]piperidines and structurally related compounds.
AID76320Oral antiallergy activity in the guinea pig anaphylaxis (GPA) model, at a pretreatment time of 24 h1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Synthesis and antiallergy activity of 4-(diarylhydroxymethyl)-1-[3-(aryloxy)propyl]piperidines and structurally related compounds.
AID167568Calcium channel-blocking activity by determined by ability to antagonize calcium-induced contractions of isolated rabbit aortic strips1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Synthesis, calcium-channel-blocking activity, and antihypertensive activity of 4-(diarylmethyl)-1-[3-(aryloxy)propyl]piperidines and structurally related compounds.
AID76322Oral antiallergy activity in the guinea pig anaphylaxis (GPA) model of, at a pretreatment time of 5 h1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Synthesis and antiallergy activity of 4-(diarylhydroxymethyl)-1-[3-(aryloxy)propyl]piperidines and structurally related compounds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (66.67)18.7374
1990's2 (33.33)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.41 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]